Allogene Therapeutics, Inc.
Company Stats
- Market Cap
- $552.8M
- as of Sep 30, 2026
- Shares Outstanding
- 345.5M
- Free Float
- 84.0%
Income Statement
- Revenue
- $0
- Operating Income
- -$209.3M
- Net Income
- -$190.9M
- EBITDA
- -$197.0M
- Non-cash Impairment
- $2.4M
Cash Flow
- Free Cash Flow
- -$149.6M
- FCF Yield
- -27.1%
- Owner FCF Yield
- -33.9%
Balance Sheet
- Cash & Equivalents
- $51.7M
Returns & Capital
- SBC, 3Y Avg
- $51.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | -$149.6M | — |
| FY2024 | $22,000 | -$201.0M | -913609.1% |
| FY2023 | $95,000 | -$239.2M | -251841.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges